Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With <i>nab</i>-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer.

导出 LinkOut

翻译打印收藏纠错

第一作者： Jonathan W,Goldman

第一单位： David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, United States.

作者： Jonathan W,Goldman ^[1] ; David M,Waterhouse ^[2] ; Ben,George ^[3] ; Peter J,O'Dwyer ^[4] ; Rafia,Bhore ^[5] ; Sibabrata,Banerjee ^[5] ; Larry,Lyons ^[5] ; Chrystal U,Louis ^[5] ; Teng Jin,Ong ^[5] ; Karen,Kelly ^[6]

作者单位： David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, United States. ^[1] Oncology Hematology Care, Cincinnati, OH, United States. ^[2] Froedtert & the Medical College of Wisconsin, Milwaukee, WI, United States. ^[3] Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, United States. ^[4] Celgene Corporation, Summit, NJ, United States. ^[5] Comprehensive Cancer Center, University of California, Davis, Sacramento, CA, United States. ^[6]

关键词 carboplatin nab-paclitaxel nivolumab non-small cell lung cancer treatment beyond progression

DOI 10.3389/fonc.2019.01256

PMID 31850192

发布时间 2020-10-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in oncology

2019年9卷

1256页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With <i>nab</i>-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With <i>nab</i>-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

检索历史清除